Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2024
Event: Entry into a Material Definitive Agreement for a public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic operating results. Key transaction metrics include:
- Securities Issued: 33,333,334 shares of Common Stock and warrants to purchase up to 33,333,334 shares.
- Offering Price: $0.30 per share and accompanying warrant.
- Gross Proceeds: Approximately $10 million (before fees and expenses).
- Warrant Terms: Exercise price of $0.35 per share; exercisable six months post-issuance; expire 5.5 years post-issuance.
- Placement Agent Fees: 7.0% of the aggregate purchase price plus up to $50,000 in expense reimbursement.
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide current revenue, profit, cash flow, or debt levels. These metrics are not applicable to this specific transaction report.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement and a Placement Agency Agreement with A.G.P./Alliance Global Partners. Key contractual restrictions include:
- Market Stand-Off: The Company agreed not to issue or announce the issuance of common stock or convertible securities for 90 days post-closing (or 60 days if a strategic transaction is announced).
- Variable Rate Transaction Restriction: No issuance involving a Variable Rate Transaction for 180 days post-closing.
- Insider Lock-Up: Directors and officers agreed not to sell or transfer Company securities for 90 days following the closing.
Outlook, Risks, and Management Commentary
Management Commentary: The Company intends to utilize the net proceeds to fund working capital and general corporate needs, indicating a focus on liquidity management to support ongoing operations.
Risks and Contingencies:
- Dilution: The issuance of 33.3 million shares and associated warrants will result in significant dilution to existing shareholders.
- Market Conditions: The offering price of $0.30 reflects current market valuations; future trading prices may fluctuate.
- Execution Risk: The offering is subject to customary conditions to closing.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting the 7% placement fee and expenses.
- Confirm the exact number of shares outstanding post-closing to assess the dilution impact on existing holdings.
- Review the Company's most recent 10-Q or 10-K for current cash balances to understand the urgency of this capital raise.
- Monitor compliance with the 90-day market stand-off and 180-day variable rate transaction restrictions.
- Check for any subsequent filings regarding the exercise of warrants or changes in the use of proceeds.